Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil oral film - Aquestive Therapeutics

Drug Profile

Tadalafil oral film - Aquestive Therapeutics

Alternative Names: AQST-119; Exordia

Latest Information Update: 15 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MonoSol Rx
  • Developer Aquestive Therapeutics
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Erectile dysfunction

Most Recent Events

  • 15 Feb 2022 Tadalafil is still in preregistration stage for Erectile dysfunction in USA (Aquestive Therapeutics pipeline, February 2022)
  • 29 Sep 2021 Aquestive Therapeutics and IntelGenx Corp. enter into an definitive license and supply agreement with an Undisclosed company to market tadalafil oral films for Erectile dysfunction and Benign prostatic hyperplasia in USA
  • 01 Sep 2019 IntelGenx plans to launch tadalafil oral film for the treatment of Erectile dysfunction in USA, in 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top